Liletta and Mirena are both levonorgestrel-releasing intrauterine devices that deliver the same 52-mg dose of the same progestin, and they share identical frame dimensions. For most people comparing the two, the practical differences come down to cost, FDA-approved indications, and the inserter design rather than how well the devices prevent pregnancy or what side effects they cause. The overlap between these two IUDs is far greater than their differences, but those differences still matter in specific situations.
Same Drug, Same Frame, Different Brand
Both Liletta and Mirena use a T-shaped polyethylene frame loaded with 52 mg of levonorgestrel, the synthetic progestin that thins the uterine lining and thickens cervical mucus to prevent pregnancy. The frames are the same size. Where they diverge physically is in the insertion hardware: Liletta’s inserter is about 2 cm longer than Mirena’s, and its diameter is slightly wider (4.8 mm compared with 4.3 mm for Mirena). Liletta’s inserter is also reloadable, while Mirena’s is not.1Contemporary OB/GYN Journal. Liletta IUS: not just for long-term contraception In practice, most people getting one placed won’t notice the difference. Your clinician might have a preference based on what they find easier to handle, but from the patient’s perspective, insertion feels similar.
Both devices are now FDA-approved for up to eight years of continuous use, which makes them among the longest-lasting reversible contraceptives available. This wasn’t always the case: each device received approval for shorter durations initially and had their labels extended as long-term trial data accumulated.
The Cost Gap Is Real
This is where the two devices diverge most sharply. Liletta was developed by Medicines360, a nonprofit pharmaceutical company, specifically to improve access to long-acting contraception. Its commercial wholesale price sits around $625, compared with roughly $811 for Mirena. But the bigger story is the 340B Drug Pricing Program, which serves safety-net clinics and hospitals caring for large numbers of low-income patients. Under that program, Liletta’s price drops to about $50, while Mirena costs around $322.2Gynecologic Oncology Reports. Comparison of Mirena and Liletta levonorgestrel intrauterine devices for the treatment of endometrial intraepithelial neoplasia and grade 1 endometrioid endometrial cancer
If you have private insurance that covers the full cost of either device, the sticker price doesn’t matter much to you personally. But in public health clinics, Title X family planning centers, and federally qualified health centers, that price difference determines which device is stocked. Liletta’s much lower 340B price is one reason it has become the default IUD in many public-sector settings since its approval in February 2015.
How Well They Prevent Pregnancy
Both devices are extremely effective contraceptives, and there is no meaningful difference in pregnancy rates between them. In a large Phase III trial of Liletta that included nearly 1,000 nulliparous women and over 600 parous women, the pregnancy rate was 0.14 per 100 users through the first year.3Contraception. Clinical Guidance: Intrauterine contraception in nulliparous women Mirena’s published efficacy is in the same range. Both are over 99% effective, making them comparable to surgical sterilization but with the advantage of being reversible.
Since the active ingredient and dose are identical, the similarity in efficacy is expected. There’s no pharmacological reason one would outperform the other at preventing pregnancy.
FDA-Approved Indications Differ
Here’s a distinction that matters in clinical settings, even if the devices themselves work the same way. Mirena carries three FDA-approved indications: contraception, treatment of heavy menstrual bleeding, and, in some label iterations, endometrial protection during estrogen therapy. Liletta is approved only for contraception.
This doesn’t mean Liletta is less effective at treating heavy periods. A study of Liletta for heavy menstrual bleeding found roughly 80% efficacy over six study cycles, matching what Mirena’s original phase III trial reported in its parous population.4PubMed Central. Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device The lack of a formal heavy-bleeding indication on Liletta’s label reflects the regulatory pathway the manufacturer pursued, not a difference in how the drug works inside the uterus. Some clinicians prescribe Liletta off-label for heavy periods, particularly in settings where cost constraints make Mirena impractical.
Similarly, research comparing Liletta and Mirena for managing precancerous endometrial changes found that Liletta was noninferior to Mirena at producing tissue regression after three, six, and nine months of use.5PubMed Central. Comparison of Mirena and Liletta levonorgestrel intrauterine devices for the treatment of endometrial intraepithelial neoplasia and grade 1 endometrioid endometrial cancer The fact that the same hormone at the same dose produces the same local effect shouldn’t surprise anyone, but having the data is useful for clinicians making coverage and formulary decisions.
Bleeding Patterns and Amenorrhea
Irregular bleeding in the first few months after placement is the norm with any 52-mg levonorgestrel IUD, regardless of brand. Most people experience lighter periods over time, and a substantial portion eventually stop menstruating altogether. A systematic review and meta-analysis of amenorrhea rates with levonorgestrel IUDs found that results were consistent with the data from Liletta’s pivotal clinical trial.6PubMed Central. Levonorgestrel intrauterine system associated amenorrhea: a systematic review and metaanalysis
The upshot is that whether you have a Liletta or a Mirena, the odds of your period getting lighter or disappearing are roughly equal. Amenorrhea can be a welcome outcome for people with heavy or painful periods, though some find the unpredictable spotting during the first three to six months frustrating. That initial adjustment period isn’t brand-specific; it’s a feature of how levonorgestrel remodels the uterine lining.
Side Effects Beyond Bleeding
The side effect profile is shared between the two devices because the drug and dose are identical. A study tracking side effects in new users of a 52-mg levonorgestrel IUD found that individual side effects like headache, mood changes, and breast tenderness were each reported on fewer than 3% of days during the first six months. The one exception was acne, which showed up more often, particularly in people switching from combined hormonal contraception like the pill. In that group, about 13% reported acne in the first 180 days, compared with roughly 9% of those who hadn’t been using hormonal birth control before.7PubMed. Hormone-related side effects in new users of a levonorgestrel 52-mg intrauterine device
The acne connection makes biological sense. Combined pills contain estrogen, which suppresses androgens and keeps skin clearer. When you switch to a progestin-only method like either IUD, you lose that estrogen-driven androgen suppression, and breakouts can follow. This isn’t a Liletta-versus-Mirena issue; it’s a class effect of progestin-only contraception.
Discontinuation for side effects ran at about 5.5% over the study period, with no difference based on what contraception participants had been using before.8PubMed. Hormone-related side effects in new users of a levonorgestrel 52-mg intrauterine device That’s a relatively low discontinuation rate, and it applies equally to both brands.
Expulsion Risk and Who It Affects
Expulsion, when the IUD partially or fully slips out of the uterus, is the complication people worry about most. A study of over 1,600 users of a 52-mg levonorgestrel IUD tracked expulsion rates over six years and found that the risk wasn’t distributed equally. Women who had only delivered vaginally had the highest expulsion rate at about 7.2%, while nulliparous women had a rate of 2.2%, and women who had delivered by cesarean fell in between at 3.1%.9PubMed. Relationship of parity and prior cesarean delivery to levonorgestrel 52 mg intrauterine system expulsion over 6 years
Obesity roughly doubled the odds of expulsion, and having had a cesarean delivery actually decreased the odds compared with vaginal-only delivery history. These findings apply to both Liletta and Mirena since the frame is identical and the risk is driven by uterine anatomy, not by the brand name on the box.
Placement right after delivery is a separate question. When a levonorgestrel IUD was inserted immediately after the placenta was delivered, the six-month expulsion rate was about 27%, considerably higher than with interval placement weeks or months later.10Contraception. A prospective cohort study comparing expulsion after postplacental insertion: the levonorgestrel versus the copper intrauterine device That elevated rate is a trade-off clinicians and patients weigh against the convenience of getting contraception handled before leaving the hospital, and it has nothing to do with which brand is used.
Use in Teens and People Who Haven’t Given Birth
Both Liletta and Mirena are safe and appropriate for adolescents and nulliparous individuals, and major professional organizations endorse IUDs as first-line options for these groups. In Liletta’s Phase III trial, two pregnancies occurred among 989 nulliparous users and four among 611 parous users, suggesting no meaningful difference in efficacy by birth history.11Contraception. Clinical Guidance: Intrauterine contraception in nulliparous women
The one area where younger users do face a different risk is expulsion. Data from the CHOICE study showed an expulsion rate of about 18% among teens aged 14 to 19, regardless of whether they had previously given birth. That rate was significantly higher than in older women. Continuation rates, though, were otherwise similar between adolescents and adults, suggesting that those who keep their IUD in place are equally satisfied with it.
Fertility After Removal
A common concern is whether long-term IUD use delays the ability to get pregnant afterward. The evidence on Liletta specifically is reassuring. Among 165 women who tried to conceive after having Liletta removed, 86% succeeded within 12 months, with a median time to conception of about three months. Those numbers didn’t vary based on whether the woman had been pregnant before, how old she was when the device was removed, or how long she’d had it in.12PubMed. Conception rates in women desiring pregnancy after levonorgestrel 52 mg intrauterine system (Liletta®) discontinuation
The 86% conception rate within a year is in line with what population-level fertility data would predict for people of reproductive age trying to get pregnant without any prior contraception. In other words, the IUD doesn’t appear to impose any lasting fertility penalty. Mirena’s return-to-fertility data tells a similar story, which again is expected given the identical drug mechanism.
Perimenopause and Endometrial Protection
For people approaching menopause who take systemic estrogen for symptom relief, a progestin is needed to protect the endometrial lining from overgrowth. The full-size 52-mg levonorgestrel IUD, whether Mirena or Liletta, can serve this role. Clinical data from European studies indicate that both devices provide effective endometrial suppression in menopausal women using estrogen therapy. The smaller levonorgestrel IUDs (Kyleena and Skyla), which release lower daily doses, lack data supporting their use for this purpose.13ResearchGate. The perimenopausal period and the benefits of progestin IUDs
This is one area where clinicians sometimes prefer Mirena simply because its labeling more directly addresses non-contraceptive uses, making insurance coverage smoother. But the pharmacology doesn’t distinguish between the two devices for this purpose.
How to Decide Between Them
For most people, the choice between Liletta and Mirena comes down to what’s available at your clinic or what your insurance covers favorably. If you’re getting care at a safety-net clinic or a 340B-eligible facility, Liletta will almost always be the more accessible option because of its dramatically lower institutional price. If you’re going through private insurance that covers both, the decision may be made by formulary preference or clinician habit.
If you specifically need your IUD for an FDA-approved non-contraceptive indication, like documented heavy menstrual bleeding, Mirena’s label may simplify insurance authorization. That said, many payers cover Liletta for contraception regardless, and the clinical performance for heavy bleeding is equivalent based on available data.
The insertion experience is marginally different because of the wider inserter on Liletta, but this is a matter of millimeters. Clinicians who do high volumes of IUD placements sometimes have preferences, but patient-reported pain and satisfaction during insertion are broadly comparable between the two.
Environmental Footprint of Hormonal IUDs
An angle that rarely comes up in the exam room but interests a growing number of people is the environmental impact of their contraceptive choice. A modeling study estimated that hormonal IUD users generate about 14 grams of cardboard and 7 grams of plastic packaging waste from the device itself, and use roughly 127 menstrual pads per year. By comparison, people not using contraception use an estimated 325 pads per year.14PubMed Central. Hormonal long-acting reversible contraceptives use and potential impact on environment: A mathematical model The reduction in menstrual product consumption is a natural consequence of lighter periods and amenorrhea. This calculation applies equally to Liletta and Mirena since both produce similar bleeding reductions. The one-time packaging waste from a device that lasts up to eight years is trivial compared with the ongoing waste from shorter-acting methods like pill packs, patch wrappers, or ring packaging replaced monthly.